Fig. 11 | Scientific Reports

Fig. 11

From: PEGylated liposomal metformin overcomes pharmacokinetic barriers to trigger potent mitochondrial disruption and cell cycle arrest in hepatocellular carcinoma

Fig. 11

Illustrates the mean docking energies (kcal/mol) and standard deviations for metformin, lenvatinib, and sorafenib across three protein targets: Bcl-2 (1G5M), CDK4–cyclin D3 (3G33), and mitochondrial Complex I (5XTD). Bars represent the average of the top ten docking poses, with error bars indicating one standard deviation.

Back to article page